Skip to main content
Contact Us
Subscribe
e-Edition
Sign up for free daily newsletters
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Home
Contact Us
Terms of Use
Privacy Policy
Subscription Services
Submission Forms
Promote Your Event
e-Edition
Place an Ad
Local Weather
News
Local News
Elections
Sports
Business
Events
Obits
Legals
Photos
Videos
e-Edition
Recent e-Editions
Archived e-Editions (Press Reader)
Classifieds
Place an ad
Submit News
Letter to the Editor
Anniversaries
Engagement
Birth Announcement
Wedding
News Tips
Other KPC Newspapers
Herald Republican (Steuben County)
News Sun (Noble and LaGrange counties)
The Star (DeKalb County)
Advance Leader (western Noble County)
Albion New Era (central Noble County)
Butler Bulletin (Butler, DeKalb County)
Garrett Clipper (Garrett, DeKalb County)
Churubusco News (Churubusco and Whitley County)
Greater Fort Wayne Business Weekly
IN|Aboite News
IN|All Sports
IN|Fort Wayne
IN|New Haven News
IN|Northwest News (Huntertown, northwest Allen County)
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
April 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
April 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
April 13, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
March 25, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
March 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 17, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
February 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
February 02, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
January 18, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
January 09, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
January 06, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
January 05, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Elects Jacqueline Wright to Its Board of Directors
December 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
December 15, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
November 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
November 09, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
November 03, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 02, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 19, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
September 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
September 18, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
September 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
September 16, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.